A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Obesity is a global health issue that impacts millions of people worldwide. Semaglutide is a glucagon-like peptide-1 receptor agonist that was initially developed as a treatment for type 2 diabetes mellitus under the brand name Ozempic. Additional st…
Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome, has emerged as the leading cause of chronic liver disease worldwide. Its global prevalence estimated at 38% between 2016-2019, represen…
BACKGROUND: Patients with overweight or obesity (OW/OB) are at increased risk for multimorbidity (≥2 obesity-related complications [ORCs]) and accompanying increases in mortality and excess costs. RESEARCH DESIGN AND METHODS: A retrospective, observa…
Over the recent years, there has been a notable surge in consumer demand for rapid and effective weight-loss pharmaceuticals that are also capable of managing type 2 diabetes. Owing to their exceptional efficacy, GLP-1 receptor agonists, including Ti…
Aim To evaluate the dynamic impact of an 8-month glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with semaglutide on anthropometric metrics, blood lipid profiles, and adipokine status in obese patients, with and without type 2 diab…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide are well-used for type 2 diabetes and obesity, and recent studies show their potential renal benefits in both diabetic and non-diabetic people. However, evidence for s…
BACKGROUND: This study evaluated the efficacy and safety of generic semaglutide compared with innovator Semaglutide in Indian adults with type 2 diabetes mellitus (T2DM). METHODS: This Phase 3, multicenter, randomized, active-controlled, non-inferior…
BACKGROUND: To examine preliminary associations between enlarged perivascular spaces (ePVS) and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment among a select cohort of Hispanic and Latino adults. The Hispanic and Lat…
INTRODUCTION: The rapid expansion of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use for weight management and diabetes has raised perioperative questions, particularly regarding delayed gastric emptying and infection risk. Emerging real-worl…
BACKGROUND: Type 2 diabetes mellitus (T2D) is a rapidly growing global health concern requiring innovative treatment methods. Ozempic (semaglutide), a glucagon-like peptide-1 receptor agonist, has proven consistent effectiveness in lowering blood glu…
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist widely used in diabetes management, has not been previously reported to interfere with PET/CT imaging. This case highlights a novel observation regarding same-day subcutaneous semagl…
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists. This review explores the evolving rol…
AIMS: Atrial fibrillation (AF) is strongly associated with adverse outcomes, particularly in patients with heart failure (HF). AF susceptibility is driven by atrial remodelling, including electrical disarray, inflammation, and fibrosis, yet current t…